問卷

TPIDB > Search Result

Search Result

篩選

List

2394Cases

2005-12-01 - 2006-12-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2005-08-01 - 2008-05-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2013-12-01 - 2016-11-30

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-10-01 - 2017-06-30

Others

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2005-07-01 - 2008-07-01

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2004-02-01 - 2006-10-01

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-10-01 - 2025-06-30

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2013-05-01 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-07-01 - 2023-06-02

Phase III

Completed
A PHASE III, RANDOMIZED, MULTICENTER, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE PHARMACOKINETICS, EFFICACY, AND SAFETY OF SUBCUTANEOUS ADMINISTRATION OF THE FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB IN COMBINATION WITH CHEMOTHERAPY IN PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER
  • Condition/Disease

    HER2-POSITIVE EARLY BREAST CANCER

  • Test Drug

    Pertuzumab and Trastuzumab FDC, Perjeta, Herceptin, Cyclophosphamide, Paclitaxel, Docetaxel, Doxorubincin

Participate Sites
4Sites

Terminated3Sites

2023-03-06 - 2030-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites